Moderna’s New European Team Readies For COVID-19 Vaccine D-Day
Gearing Up For A Huge Commercial And Manufacturing Challenge
Executive Summary
After a stunning first efficacy readout for its mRNA-based vaccine, the biotech company's leaders in Europe talk about their rapid commercial and manufacturing scale-up.
You may also be interested in...
AZ Will Sideline ‘Lucky Mistake’ To Secure COVID-19 Vaccine Approval
A lower first dose boosted the vaccine’s efficacy result – but AstraZeneca has conceded this has to be proven in a separate trial.
Moderna Aces COVID-19 Vaccine Results With 94.5% Efficacy
Moderna’s stunning interim results add to the world’s relief brought by Pfizer’s first read-out, and also provide the US biotech with the commercial platform it needed
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.